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Background: Serum C-reactive protein (CRP) and leptin levels have been independently associated with the
cardiovascular risk factors. The aim of the present study was to determine if their serum levels were associated with
cardiovascular risk factors or metabolic syndrome as well as their correlation in the Taiwanese population.
Methods: This retrospective study included 999 subjects (> 18 y), who underwent a physical examination in
Chang-Gung Memorial Hospital-Linkou and Chiayi in Taiwan. The associations between CRP and/or leptin levels and
cardiovascular risk factors and metabolic syndrome were determined using independent two sample t-tests to
detect gender differences and chi-square tests to evaluate differences in frequencies. To compare the means of the
variables measured among the four groups (high and low leptin and high and low CRP), analysis of variance
(ANOVA) was used.
Results: Both CRP and leptin levels were independently associated with several cardiovascular risk factors, including
diabetes, hypercholesterolemia and metabolic syndrome in both men and women (P< 0.05). In addition, a positive
correlation between leptin and CRP levels was observed in both genders. Both high-CRP and high-leptin were
associated with high blood glucose, waist circumference and serum triglyceride. Whereas increased metabolic
syndrome incidence was observed in males with elevated leptin regardless of CRP levels, females with elevated CRP
or leptin had increased incidence of metabolic syndrome.
Conclusion: Both leptin and CRP levels were associated with cardiovascular risk factors as well as metabolic
syndrome score in both men and women although gender-specific differences were observed. Thus, CRP and
leptin may represent useful biomarkers for predicting the onset of cardiovascular disease or metabolic syndrome in
Taiwanese adults.
Trial registration: IRB/CGMH 100-3514B
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Because a combination of several cardiovascular and dia-
betes risk factors comprise metabolic syndrome, it has
been postulated that factors involved in both diseases
may interact. Two such factors include leptin and C-* Correspondence: 620313@adm.cgmh.org.tw
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reproduction in any medium, provided the orreactive protein (CRP), and both are associated with in-
dices of obesity and cardiovascular disease.
CRP is an inflammatory marker of cardiovascular dis-
ease [1]; elevated levels are associated with increased risk
of future coronary heart disease [2-4]. Obesity is one of
the strongest determinants of CRP levels [5]. Further-
more, CRP has been related to metabolic syndrome in
several studies [2,6], and its production is influenced by
leptin [7].
Leptin is expressed by adipose tissue [8], regulating
appetite and energy expenditure as well as insulind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drome development independent of obesity [10]. In
men [11] and patients with type 2 diabetes [12], leptin
levels were associated with cardiovascular disease. This
association may be through inflammatory mechanisms
since leptin and CRP levels have been correlated in a
variety of patient populations [13-17].
In addition to cardiovascular disease, CRP and leptin
levels are predictive of metabolic syndrome develop-
ment. In middle-aged subjects, high leptin in men and
high CRP in women were significant predictors of meta-
bolic syndrome; those with elevations in both markers
had the highest risk of developing metabolic syndrome
[18]. However, the effects of CRP and leptin levels in a
Taiwanese population have yet to be determined.
The objective of the present study was to determine if
CRP and leptin levels are associated with cardiovascular
disease risk factors as well as metabolic syndrome score
in healthy Taiwanese adults. In addition, the possible
correlation between CRP and leptin levels was also
explored in this population. CRP and leptin may repre-
sent useful biomarkers for predicting the onset of car-
diovascular disease or metabolic syndrome in Taiwanese
adults.Methods
Study population
In 2010, 1025 subjects (> 18 y), who had undergone a
routine physical examination in Chang-Gung Memorial
Hospital-Linkou (North Taiwan) and Chiayi (SouthTable 1 Subject characteristics by gender
Men (n= 720)
Age (y)1 35.79 ± 7.94
MS, n (%)2 61 (8.5)
Diabetes mellitus, n (%)2 19 (2.6)
BMI (kg/m2)1 24.70 ± 3.43
Waist circumference (cm)1 81.76 ± 10.35
Systolic BP (mm Hg)1 125.14 ± 13.27
Diastolic BP (mm Hg)1 78.69 ± 9.96
Fasting blood glucose (mg/dL)1 88.79 ± 12.69
Total cholesterol (mg/dL)1 183.85 ± 32.84
LDL cholesterol (mg/dL)3 119 (99, 139)
HDL cholesterol (mg/dL)3 50 (43, 59)
Triglycerides (mg/dL)3 91 (65, 128)
Uric acid (mg/dL)1 6.28 ± 1.51
Leptin (ng/mL)3 4.99 (3.03, 8.18)
CRP (μg/mL)3 0.77 (0.42, 1.72)
P-values are based on 1independent two sample t-test, 2Chi-square, or 3Mann-Whitn
median (interquartile). Abbreviations: MS, metabolic syndrome; BMI, body mass inde
lipoprotein; and CRP, C-reactive protein.Taiwan), were selected to participate in this retrospective
study. Participants were included if they had undergone
a physical exam in which the following parameters were
assessed: weight, height, blood pressure, waist circumfer-
ence, total cholesterol, triglyceride, fasting glucose, high
density lipoprotein- cholesterol (HDL-C), low density
lipoprotein-cholesterol (LDL-C), CRP, and leptin.
Patients were exclude if they had not fasted for 12 h,
were pregnant, or had a history of cardiovascular disease
(e.g., myocardial infarction or stroke),chronic inflamma-
tory disease (e.g., chronic rheumatoid arthritis, hepatitis,
and cancer), or endocrine disease (e.g., hyperthyroidism
or hypothyroidism). The study was approved by the In-
stitute Reviewing Board of Chang Gung Memorial
Hospital. As shown in Table 1, after 26 participants were
excluded, a total of 999 participants were analyzed, in-
cluding 720 males (35.79 ± 7.94 y) and 279 females
(38.60 ± 12.80 y).
Participants were interviewed by trained nurses. Infor-
mation regarding demographic (e.g., age, gender, etc.)
and life style characteristics (e.g., history of smoking,
drinking, etc.), history of illness and medication use, and
physiological status (e.g., pregnancy, fasting time, etc.)
was collected (Table 1).Blood pressure, BMI, and waist circumference
measurements
Systolic and diastolic blood pressures were measured
with a random zero sphygmomanometer while patients
were in sitting position after a 5-min period of rest,Women (n = 279) P-value
38.60 ± 12.80 0.001
59 (21.1) <0.001
8 (2.9) 0.842
21.90 ± 3.19 <0.001
82.51 ± 9.67 0.294
113.08± 15.12 <0.001
70.56 ± 9.83 <0.001
90.09 ± 21.21 0.233
184.53± 30.42 0.335
120 (99, 141) 0.855
50 (42, 59) 0.959
96 (68, 142) 0.119
6.43 ± 1.50 0.163
5.51 (3.21, 9.56) 0.089
0.85 (0.44, 1.79) 0.407
ey U test. Data are displayed as 1 mean ± SD, 2number (percentage), or 3
x; BP, blood pressure; LDL, low density lipoprotein; HDL, high density
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enth Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure
recommendations [19], and the average of up to three
independent measurements was used.
To determine body mass index (BMI), the height and
weight of each patient were measured using an auto-
matic scale. BMI was calculated as weight (kg) divided
by the height squared (m2).
Waist circumference was determined with the patient
standing with their feet 25 to 30 cm apart. It was mea-
sured midway between the iliac crest and the lower mar-
gin of the 12th rib.Laboratory measurements
After a 12-h fast, venous blood samples were obtained
between 5:30 to 11:00 a.m. and stored at 4°C. Total chol-
esterol, HDL-C, triglyceride (TG), fasting blood glucose
(FBG), LDL-C, and leptin levels were determined for
each participant. CRP was determined using a high sen-
sitivity CRP assay.Cardiometabolic risk factor variables
Individuals were considered hypertensive if they were
taking antihypertensive medications, self-reported a
diagnosis of hypertension, if their systolic pressure was
> 140 mmHg or diastolic pressure was> 90 mmHg, or
if a combination of these features was recorded [20].
Participants were considered to have diabetes if they
reported a current usage of antidiabetic medications,
reported a previous diagnosis of diabetes, or had a FBG
> 126 mg/dL [21].
A patient was considered to have dyslipidemia if they
had the following: plasma TC ≥ 240 mg/dL and/or use of
medications to lower blood cholesterol, TG ≥ 200 mg/dL,Table 2 Leptin levels in patients with and without cardiovasc
Men (n = 720)
Absent Present
Diabetes 4.96 (2.97, 8.02) 6.97 (4.90, 8.56)
Hypercholesterolemia 4.94 (2.97, 7.85) 8.02 (4.56, 11.50)
Hypertriglyceridemia 4.91 (2.94, 7.89) 7.18 (4.44, 10.30)
High LDL cholesterol 4.92 (2.94, 7.85) 6.36 (3.73, 10.20)
Low HDL cholesterol 4.95 (2.94, 8.32) 5.04 (3.68, 7.43)
Hypertension 4.94 (2.97, 8.20) 5.51 (3.11, 7.93)
MS 4.78 (2.90, 7.73) 7.26 (4.98, 9.52)
Ever smoked 4.82 (2.90, 7.60) 5.53 (3.35, 9.34)
Alcohol use 4.63 (2.89, 7.54) 5.25 (3.28, 8.57)
P-values are based on Mann–Whitney U test.
Data are displayed as median (interquartile).
Abbreviations: LDL, low density lipoprotein; HDL, high density lipoprotein; and MS,HDL-C< 40 mg/dL, and LDL-C ≥ 160 mg/dL and/or use
of medications to lower LDL-C [22].
Regarding tobacco and alcohol use, those who had
smoked ≥ 100 cigarettes in their lifetime were considered
to have “ever smoked”. Alcohol use was defined as any
alcohol use within the last year.
Leptin concentrations >4.99 ng/mL in men and
>5.51 ng/mL in women were defined as “high”. CRP
values >3 μg/mL in both men and women were defined
as “high”.Definition of metabolic syndrome
A participant was diagnosed with metabolic syndrome if
they presented with at least three of the following five
factors: 1) high blood pressure (systolic blood pressure
≥ 130 mmHg and/or diastolic pressure ≥ 85 mmHg,
under treatment, or current hypertension diagnosis); 2)
high serum triglyceride (≥ 150 mg/dL or under treat-
ment); 3) decreased HDL-C (< 40 mg/dL for males and
< 50 mg/dL for females or under treatment); 4) hyper-
glycemia (FBG ≥ 100 mg/dL, under treatment, or diagno-
sis with diabetes mellitus); and 5) abdominal obesity
[23]. Modified waist circumference cutoffs for Asian
populations were used, which consisted of a waist cir-
cumference ≥ 90 cm for men and ≥ 80 cm for women
[24].Statistical analysis
To compare the variables by gender or presence, inde-
pendent two sample t-tests were used. For evaluating
differences in frequencies, the chi-square test was used.
Because leptin and CRP levels were not normally distrib-
uted, Mann–Whitney U tests were used.
To compare the means of the variables among the
four groups (high and low leptin and high and low
CRP), analysis of variance (ANOVA) was used. If theular disease risk factors
Women (n= 279)
P-value Absent Present P-value
0.044 5.50 (3.14, 9.40) 8.65 (4.79, 12.35) 0.049
0.003 5.43 (3.14, 9.40) 8.05 (5.67, 13.95) 0.039
0.002 5.39 (3.12, 9.22) 6.90 (4.90, 10.75) 0.054
0.013 5.43 (3.17, 9.87) 6.15 (4.45, 9.13) 0.561
0.610 5.51 (3.12, 9.96) 5.51 (3.32, 9.13) 0.698
0.538 5.40 (3.12, 9.36) 7.67 (4.35, 11.20) 0.087
<0.001 5.20 (2.94, 9.74) 6.63 (4.83, 9.40) 0.010
0.030 5.51 (3.17, 9.56) 5.71 (4.57, 6.72) 0.829
0.057 5.53 (3.32, 9.72) 5.40 (2.89, 9.40) 0.548
metabolic syndrome.
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was performed. When a significant difference between
groups was apparent, multiple comparisons were per-
formed using the Bonferroni procedure with type-I
error adjustment. The correlation between leptin and
CRP was determined using Spearman’s correlation co-
efficient. The partial correlations between metabolic
syndrome components and CRP and leptin were calcu-
lated while controlling for age, or age and BMI. All
statistical assessments were two-sided and considered
significant when P< 0.05. Statistical analyses were per-




As shown in Table 1, the characteristics of the study
subjects were compared by gender, and significant differ-
ences were observed. Specifically, women were signifi-
cantly older and had a significantly lower BMI and
systolic and diastolic blood pressures as compared to
men (P ≤ 0.001). In addition, the prevalence of metabolic
syndrome was significantly lower in male participants
(8.5 vs. 21.1%, P< 0.001). No gender differences in leptin
or CRP levels were observed.
Associations between leptin and CRP levels with
cardiovascular risk factors
Serum leptin levels were evaluated to determine if they
were associated with cardiovascular risk factors in
Taiwanese adults as previously reported in men [11] and
those with type 2 diabetes [12]. In both men and
women, diabetes, hypercholesterolemia and metabolic
syndrome were significantly associated with elevated lep-
tin levels (Table 2). In addition, gender differences were
observed; men who were ever tobacco users, as well asTable 3 CRP levels in patients with and without cardiovascula
Men (n = 720)
Absent Present
Diabetes 0.76 (0.42, 1.67) 1.70 (0.55, 2.99)
Hypercholesterolemia 0.75 (0.41, 1.67) 1.41 (0.81, 2.29)
Hypertriglyceridemia 0.74 (0.40, 1.65) 1.34 (0.76, 2.47)
High LDL cholesterol 0.73 (0.40, 1.65) 1.14 (0.62, 2.04)
Low HDL cholesterol 0.72 (0.39, 1.53) 1.41 (0.67, 2.61)
Hypertension 0.77 (0.41, 1.72) 0.78 (0.47, 1.68)
MS 0.72 (0.40, 1.55) 1.84 (0.87, 2.77)
Ever smoked 0.76 (0.43, 1.70) 0.80 (0.40, 1.72)
Alcohol use 0.74 (0.41, 1.70) 0.80 (0.44, 1.72)
P-values are based on Mann–Whitney U test.
Data are displayed as median (interquartile).
Abbreviations: CRP, C-reactive protein; LDL, low density lipoprotein; HDL, high densthose with hypertriglyceridemia and high LDL-C had
significantly higher leptin levels. No such associations
were detected in women.
In both genders, those with diabetes, hypercholesterol-
emia, hypertriglyceridemia, low HDL-C, and metabolic
syndrome all had significantly higher CRP levels
(Table 3). High LDL-C was associated with high CRP
levels in men only. In addition, a significantly positive
correlation between leptin and CRP levels was observed
in both genders (P< 0.001, Figure 1).
As shown in Table 4, male participants with high con-
centrations of both leptin and CRP had a significantly
greater waist circumference, metabolic syndrome inci-
dence, FBG, and triglyceride levels and lower HDL-C
than individuals with low concentrations of both leptin
and CRP (P< 0.017). Moreover, female participants with
high concentrations of both leptin and CRP had signifi-
cantly greater waist circumference, FBG, triglyceride and
LDL-C levels than individuals with low leptin and CRP
concentrations (P< 0.017, Table 4).
Associations between leptin and CRP levels with
metabolic syndrome
The associations between leptin and CRP levels with
metabolic syndrome score, which is determined as the
number of metabolic syndrome components described by
the ATP III criteria [23], was next determined. Leptin con-
centrations varied in relation to the metabolic syndrome
score in both genders (Figure 2). After adjusting for age,
leptin levels significantly increased with increasing meta-
bolic syndrome score in both male and female subjects
(Figure 2, left panels; P< 0.05). Upon additional adjust-
ment for BMI, the association between elevated leptin
levels with metabolic syndrome score remained in both
male (P< 0.001) and female (P=0.002) subjects (Figure 2,
right panels). Similar associations were observed for CRPr disease risk factors
Women (n = 279)
P-value Absent Present P-value
0.044 0.82(0.43, 1.62) 2.42 (1.81, 4.06) 0.001
0.002 0.82 (0.43, 1.64) 1.79 (1.15, 2.96) 0.013
<0.001 0.79 (0.39, 1.62) 1.46 (0.77, 2.09) 0.013
0.001 0.84 (0.40, 1.62) 1.21 (0.52, 2.76) 0.217
<0.001 0.73 (0.39, 1.38) 1.06 (0.53, 2.14) 0.002
0.659 0.79 (0.42, 1.57) 1.56 (0.77, 3.72) 0.012
<0.001 0.76 (0.39, 1.55) 1.33 (0.66, 2.81) 0.001
0.291 0.83 (0.44, 1.69) 1.09 (0.85, 3.24) 0.279
0.590 0.79 (0.42, 1.67) 1.05 (0.48, 2.00) 0.239
ity lipoprotein; and MS, metabolic syndrome.
Figure 1 The correlation between leptin and CRP. The Spearman
correlation coefficient between fasting plasma leptin and CRP was
determined for both male (A) and female (B) participants. *For male
participants, the Spearman correlation coefficient = 0.293, P< 0.001.
For female participants, spearman correlation coefficient = 0.307,
P< 0.001.
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increased with increasing metabolic syndrome score in
both male and female subjects (P< 0.001). Upon add-
itional adjustment for BMI, the association of CRP with
metabolic syndrome score remained significant in both
male and female subjects (P< 0.001).
Discussion
This is the first study to explore the possible association
and interaction between leptin and CRP levels with risk
factors for cardiovascular disease and metabolic syn-
drome in a Taiwanese population. Both leptin and CRP
levels were associated with cardiovascular risk factors as
well as metabolic syndrome score in both men and
women as in Xu et al. [25] although gender-specific dif-
ferences were observed. Specifically, significant correla-
tions were observed between both leptin and CRP levels
with diabetes, hypercholesterolemia, and metabolicsyndrome; however, gender differences were identified
regarding the association between these markers and the
presence of individual cardiovascular disease risk factors.
Furthermore, individuals with both high leptin and high
CRP levels had significantly greater waist circumference,
glucose levels, triglyceride levels as compared to those
with low leptin and low CRP levels. Elevated leptin and
low CRP levels were associated with metabolic syndrome
in both men and women. Finally, a positive correlation
between leptin and CRP levels was observed as com-
pared to previous reports [17,18].
In a previous report, we observed that leptin levels
were associated with cardiovascular disease risk factors
[26]. In this study, further associations between leptin
and CRP levels and metabolic syndrome score were
detected in both male and female participants. This is
different from a previous report by Ukkola et al. in
which metabolic syndrome scores were associated with
high leptin and high CRP in men and with high CRP
only in women after stratification by BMI in a Finish
population [18]. Thus, there may be population-specific
differences in the correlation between BMI and leptin
level, which will require further studies to elucidate.
The association between leptin and metabolic syndrome
is not fully understood. Leptin receptors are found on pan-
creatic β cells, suppressing insulin secretion [27]. In leptin
resistance, glucose-stimulated insulin secretion is not sup-
pressed by leptin, which may lead to insulin resistance [28].
Further studies are required to determine the exact role of
leptin in metabolic syndrome.
As previously reported in a Finnish population [17] as
well as Japanese type 2 diabetic patients [13] and healthy
individuals [29], an association between leptin and CRP
was observed in the Taiwanese cohort analyzed in the
present study. The mechanisms linking leptin with CRP
are not well known. Among the proinflammatory cyto-
kines, CRP synthesis is primarily regulated by interleu-
kin-6 (IL-6) [30]. Proinflammatory cytokines, which
include IL-6, IL-1 and tumor necrosis factor-alpha
(TNF-α) are secreted not only by adipocytes but also by
inflammatory cells, such as adipose-resident macro-
phages [31-33]. These cytokines may stimulate leptin se-
cretion from human adipose tissue as well as hepatic
CRP synthesis [34,35]. However, leptin itself can stimu-
late the production of various cytokines, including IL-6
[36]. Thus, IL-6 and leptin may positively regulate the
other’s expression through a feedback loop. Because the
leptin receptor mediates intracellular signaling with a
specificity similar to IL-6-type receptors [37], leptin may
regulate CRP production not only via IL-6 but also via
the leptin receptor. In addition, Chen et al. [38] demon-
strated that physiological concentrations of leptin can
dose-dependently stimulate CRP expression in human
primary hepatocytes. An alternative explanation is that
Table 4 Baseline characteristics by leptin and CRP level


















Age (y)1 35.97 ± 7.76 35.76 ± 10.26 35.85 ± 8.02 34.58 ± 7.48 36.71 ± 13.65 42.56 ± 15.17 40.15 ± 11.73 37.90 ± 10.45
BMI (kg/m2)1 24.84 ± 3.55 24.22 ± 4.07 24.63 ± 3.38 24.49 ± 2.73 21.66 ± 3.13 22.03 ± 2.95 21.96 ± 3.23 22.90 ± 3.40
Waist circumference (cm)1 79.72 ± 7.90 78.17 ± 9.67 82.32 ± 11.42b 91.56 ± 10.99b 79.95 ± 7.77 84.54 ± 5.24 84.26 ± 10.62 86.04 ± 13.07b
MS, n (%)2 14 (4.2) 2 (8.0) 34 (11.4)b 11 (17.7)b 17 (13.8) 6 (37.5)b 31 (26.1)b 5 (23.8)
Ever smoked, n (%)2 98 (29.3) 7 (28.0) 101 (33.9) 24 (31.9) 4 (3.3) 1 (6.3) 3 (2.5) 2 (9.5)
Alcohol use, n (%)2 170 (50.7) 13 (52.0) 173 (58.1) 31 (50.0) 25 (20.3) 3 (18.8) 20 (16.8) 7 (33.3)
Systolic BP (mm Hg)1 124.86 ± 11.35 128.12 ± 24.54 125.89 ± 14.25 121.79 ± 11.21 111.02 ± 12.10 117.56 ± 15.60 113.81 ± 15.78 117.62 ± 23.81
Diastolic BP (mm Hg)1 78.32 ± 8.95 80.96 ± 16.48 79.27 ± 10.40 76.98 ± 9.53 69.06 ± 9.23 72.00 ± 9.65 71.32 ± 9.43 73.90 ± 14.05
Fasting blood glucose (mg/dL)1 87.66 ± 9.29 87.12 ± 6.950 88.51 ± 10.71 96.87 ± 27.80b 87.20 ± 8.06 103.13 ± 63.91b 89.25 ± 8.66 101.90 ± 44.87b
Total cholesterol (mg/dL)1 181.40 ± 29.75 172.64 ± 30.46 185.68 ± 35.19 192.79 ± 35.93 178.28 ± 27.46 189.63 ± 37.21 190.00 ± 31.80b 186.24 ± 28.59
Triglycerides (mg/dL)3 87 (64, 117) 84 (61, 99) 98 (64, 135) 125 (79, 153)b 86 (65, 125) 119 (73, 155) 101 (68, 159) 136 (83, 151)b
LDL cholesterol (mg/dL)3 118 (99, 138) 117 (99, 129) 120 (96, 139) 126 (112, 150) 113 (95, 133) 121 (110, 155) 124 (102, 144) 129 (109, 141)b
HDL cholesterol (mg/dL)3 51 (43, 59) 46 (40, 53) 51 (43, 60) 45 (40, 50)b 51 (44, 59) 42 (38, 50)b 51 (43, 61) 50 (40, 55)
a The low leptin-low CRP group was considered the reference group.
b indicates a significant difference between indicated group and the reference group,
P-values are based on 1 ANOVA test, 2 Chi-square, or 3 Kruskal-Wallis test.
Data are displayed as 1 mean ± SD, 2number (percentage), or 3 median (interquartile).

















Figure 2 Relationship between fasting plasma leptin concentrations and metabolic syndrome score. The association between fasting
plasma leptin concentration and metabolic syndrome score was determined for male (A) and female (B) participants and adjusted for either age
(left panel) or age and BMI (right panel).
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cytokine regulating CRP synthesis without a causal rela-
tionship between leptin and CRP. However, further stud-
ies are necessary to determine the exact intracellular
mechanisms by which leptin regulates CRP production.
Furthermore, a role for CRP in the development ofFigure 3 Relationship between fasting plasma CRP levels and metabo
level and metabolic syndrome score was determined for male (A) and fem
BMI (right panel).leptin resistance has also been suggested, but needs to
be further analyzed [39,40].
In the present study, leptin and CRP levels were asso-
ciated with metabolic syndrome score, indicating that
high levels of these markers may be predictive of devel-
oping metabolic syndrome similarly to that shown forlic syndrome score. The association between fasting plasma CRP
ale (B) participants and adjusted for either age (left panel) or age and
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up analysis will be undertaken to fully evaluate the pre-
dictive value of these markers using a prediction model
as was used by Chien et al. [42].
Differences in cardiovascular risk have been observed
in obese individuals with and without adipose tissue in-
flammation. In a recent study by Farb et al. [43], higher
plasma insulin, triglyceride, glucose, blood pressure,
LDL-C and high sensitivity CRP and lower HDL-C were
observed in individuals with inflamed adipose. Further
studies are necessary to determine if adipose inflamma-
tion alters the association of CRP and leptin with meta-
bolic syndrome in obese individuals.
Limitations of this study include its retrospective,
cross-sectional nature. In addition, the data used in the
present study was collected during a routine physical
examine. Because examination of CRP and leptin levels
was by choice, this may select for individuals concerned
about weight and/or metabolic problems. Furthermore,
no information regarding exercise and diet as well as
hereditary disease was collected.
Conclusions
In conclusion, this study suggests that leptin and CRP
are strong predictors of not only cardiovascular disease
but also metabolic syndrome in Taiwanese men and
women. The associations between leptin and CRP with
cardiovascular disease risk factors and metabolic syn-
drome score may provide a tool for assessing the risk of
developing these diseases although further longitudinal
studies in larger patient populations are necessary to de-
termine the predictive value of examining their levels.
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